Entest Group Inc is a blank check company. The Company is formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses or entities. The Companyâ€™s current business plan is to seek new business opportunities or to engage in a business combination with an unidentified company. The Company has no operations and has not generated revenues.

Employees

Sector

Investment Holding Companies

More about the company

Delayed OTC Markets 09:31:58 2026-07-13 EDT			5-day change	1st Jan Change
0.000200 ^USD	-.--%		-.--%	-

20-01-21	Entest Group, Inc. Reports Earnings Results for the First Quarter Ended November 30, 2019	CI
19-12-20	Entest Group, Inc. Reports Earnings Results for the Full Year Ended August 31, 2019	CI

Market Cap	541K 463K 432K 396K 745K 51.75M 760K 5.13M 2M 25.94M 2.03M 1.99M 85.87M	P/E 2018	-0.92x	P/E 2019	12.6x
Enterprise Value	562K 481K 449K 412K 774K 53.78M 789K 5.33M 2.08M 26.95M 2.11M 2.06M 89.23M	EV / Sales 2018	-	EV / Sales 2019	-
Free-Float	98.54%	Yield 2018 *	-	Yield 2019	-

20-01-21	Entest Group, Inc. Reports Earnings Results for the First Quarter Ended November 30, 2019	CI
19-12-20	Entest Group, Inc. Reports Earnings Results for the Full Year Ended August 31, 2019	CI
19-07-15	Entest Group, Inc. Reports Earnings Results for the Third Quarter Ended May 31, 2019	CI
19-01-22	Entest Group, Inc. Reports Earnings Results for the First Quarter Ended November 30, 2018	CI
18-12-03	Entest Group, Inc. Announces Management Changes	CI
18-11-26	Peiwen Yu completed the acquisition of 48.3% stake in Entest Group, Inc. from Regen BioPharma, Inc., Bostonia Partners, Inc, Dunhill Ross Partners, Inc., Bio-Technology Partners Business Trust, David Koos and Sherman Family Trust.	CI
18-11-19	Peiwen Yu entered into an agreement to acquire 48.3% stake in Entest Group, Inc. from Regen BioPharma, Inc., Bostonia Partners, Inc, Dunhill Ross Partners, Inc., Bio-Technology Partners Business Trust, David Koos and Sherman Family Trust for $0.33 million.	CI
18-02-14	ENTB will Change its Name to ETNI	CI
15-11-26	Entest Group, Inc. Auditor Raises 'Going Concern' Doubt	CI
15-08-21	Entest Biomedical, Inc. will Change its Ticker to ENTB from ENTB.D	CI
15-07-27	Entest Biomedical, Inc. will Change its Ticker to ENTBD from ENTB	CI
14-07-16	Christine Ichim Joins Entest BioMedical Inc. as Director of Research	CI
13-03-06	Entest Biomedical Mulls Acquisitions	CI

20-01-21	ENTEST : Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)	AQ
20-01-07	ENTEST GROUP, INC. : Changes in Registrant's Certifying Accountant (form 8-K)	AQ
19-12-20	ENTEST : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K)	AQ
18-05-10	Entest Group, Inc. : Declares Property Dividend of 3,000,000 Common Shares of Zander Therapeutics Inc.	PR
17-09-13	Entest Biomedical : Zander Therapeutics, Inc. Announces Appointment of Dr. Robin Beat Gasser to Scientific Advisory Board	PR

Entest Group, Inc. Stock

Stocks

ETNI

US29383T3005

Investment Holding Companies

Valuation: Entest Group, Inc.

Chart: Entest Group, Inc.

Latest news : Entest Group, Inc.

Press Releases: Entest Group, Inc.

Course Extremes

Managers and Directors: Entest Group, Inc.

Shell Companies

Financials

Company Profile

Current year	0		0
1 year	0		0.01
3 years	0		0.01
5 years	0		0.02
10 years	0		0.09

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ENTEST GROUP, INC.	-.--%	-.--%	-98.00%	-33.33%	9.83K
CHURCHILL CAPITAL CORP XI	+4.09%	-13.71%	-	-	784M
CENTIEL AG	-7.45%	-7.18%	+289.16%	-70.90%	713M
DRUGS MADE IN AMERICA ACQUISITION II CORP.	+0.20%	+0.10%	-	-	646M
BAIN CAPITAL GSS INVESTMENT CORP.	-0.39%	+0.29%	-	-	603M
CHURCHILL CAPITAL CORP XII	-0.28%	+0.05%	-	-	600M
CANTOR EQUITY PARTNERS IV, INC.	-0.48%	-0.77%	-	-	594M
AMERICAN EXCEPTIONALISM ACQUISITION CORP. A	+0.47%	+1.65%	-	-	575M
CHURCHILL CAPITAL CORP XIII	+0.10%	-0.85%	-	-	508M
Average	-0.46%	-1.59%	+95.58%	-52.12%	557.94M
Weighted average by Cap.	-0.51%	-2.22%	+289.15%	-70.90%

	2018	2019
Net sales	-	-
Net income	-1.48M -1.27M -1.18M -1.08M -2.04M -141M -2.08M -14M -5.46M -70.85M -5.55M -5.43M -235M	192K 164K 153K 140K 264K 18.33M 269K 1.82M 708K 9.19M 719K 704K 30.42M
Net Debt	19.4K 16.61K 15.5K 14.22K 26.72K 1.86M 27.25K 184K 71.67K 930K 72.84K 71.26K 3.08M	21.2K 18.15K 16.93K 15.54K 29.2K 2.03M 29.77K 201K 78.31K 1.02M 79.59K 77.86K 3.37M